Author’s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Restricted accessLetterFirst published online January, 2018
Author’s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd-JonesDMMorrisPBBallantyneCMet al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92-125.
2.
StoneNJRobinsonJGLichtensteinAHet al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.
3.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
4.
GrundySMCleemanJIMerzCNet al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
5.
JacobsonTAItoMKMakiKCet al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1—full report. J Clin Lipidol. 2015;9:129-169.
6.
JacobsonTAMakiKCOrringerCet al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1-S122.
7.
BathumLDepont ChristensenREngers PedersenLLyngsie PedersenPLarsenJNexoeJ. Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. Scand J Prim Health Care. 2013;31:172-180.
8.
SabatineMSGiuglianoRPKeechACet al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722.
9.
GiuglianoRPWiviottSDBlazingMAet al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;5:547-555.
10.
CannonCPBlazingMAGiuglianoRPet al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
11.
RavnskovUMcCullyKSRoschPJ. The statin-low cholesterol-cancer conundrum. QJM. 2012;105:383-388.
12.
TothPPDescampsOGenestJet al. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation. 2017;135:1819-1831.
13.
KorenMJSabatineMSGiuglianoRPet al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2:598-607.
14.
GiuglianoRPMachFZavitzKet al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633-643.
